acticor biotech sas logo

Acticor Biotech SAS

Acticor Biotech develops an innovative treatment to reduce death, disabilities and recurrence of acute ischemic #stroke Acticor Biotech is a biotechnology company, engages in developing therapeutic monoclonal antibodies and anti platelet agents for the treatment of ischemic strokes.

Acticor is a spin-off company from Inserm founded by M. Jandrot-Perrus, P. Billiald and C. Gachet, supported by institutions including the ANR (The French National Research Agency), the Fondation de France and the prize for Innovation from SGAM (Soci_t_ G_n_rale Asset Management)

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://acticor-biotech.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Hôpital Bichat – INSERM U1148 46, rue Henri Huchard 75018
Paris
France
Email
Contact Number
+33 1 40 98 07 75

In Mar 2016, Acticor outsourced Catalents proprietary GPExÎ technology for the development of its Fab candidate, ACT-017, targeting the platelet glycoprotein VI (GPVI).

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/acticor-biotech” connections=”true” suffix=””]

Acticors product is an antibody (Fab) directed against a new therapeutic target and the platelet glycoprotein VI (GPVI) target for anti-thrombotic treatments. The protein was cloned at the Inserm by Dr. Martine Jandrot-Perrus team, and is considered as one of the most promising targets for stroke treatment.

In Feb 2015, Acticor Biotech raised 670kã from Business Angels and crowdfunding. Other funding partners includes BioPharmAnalyses, Les Echos and Biotech Finances.

In July 2016, Acticor Biotech secure ã1.4 million via the Anaxago crowdfunding platform.

Feb 2017, Acticor Biotech from the investor CapDecisif Management raised ã1,5M to pursue the development of its lead candidate ACT017 in Acute Ischemic Stroke, toward its entry in Phase I Clinical Trial.

In Jan 2018, Acticor closes ã1,7M of an equity financing led by Primer Capital and historical shareholders – Anaxago, CapDecisif Management and grants from Concours Mondial de lInnovation for ã2,2 million.